Neurotech International Ltd. (AU:NTI) has released an update.
Neurotech International Ltd’s recent publication in ‘Journal Biomolecules’ highlights the promising benefits of their low-THC cannabis extract, NTI164, in reducing neuroinflammation and protecting neurons. The findings suggest NTI164 offers enhanced therapeutic effects over traditional CBD, making it a strong candidate for treating disorders like Autism and Rett Syndrome. With positive clinical trial outcomes, Neurotech is gaining attention for its innovative approach to pediatric neurological disorders.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.